单纯血管内治疗与静脉阿替普酶联合血管内治疗对急性缺血性卒中患者功能独立的影响:DEVT随机临床试验
DEVT多中心随机非劣效试验在中国33家卒中中心纳入234例前循环近端颅内闭塞、发病4.5小时内且适合静脉溶栓的患者,随机分为单纯血管内取栓组(116例)和静脉阿替普酶联合血管内取栓组(118例)。90天功能独立(mRS 0-2)比例单纯组54.3% vs 联合组46.6%,差异7.7%(单侧97.5%CI -5.1%至∞),非劣效P=0.003。症状性颅内出血(6.1% vs 6.8%)和90天死亡率(17.2% vs 17.8%)组间无显著差异。试验因疗效在计划970例中仅入组234例时提前终止。
要点
- 前循环近端闭塞且发病4.5小时内适合静脉溶栓者,单纯取栓90天功能独立54.3% vs 联合溶栓46.6%,满足预设非劣效界值-10%(差异7.7%,单侧97.5%CI -5.1%至∞,非劣效P=0.003)。
- 症状性颅内出血48小时内单纯组6.1% vs 联合组6.8%,差异-0.8%(95%CI -7.1%至5.6%),无显著差异。
- 90天死亡率单纯组17.2% vs 联合组17.8%,差异-0.5%(95%CI -10.3%至9.2%),无显著差异。
- 试验因疗效提前终止,仅随机234例(计划970例),结论需结合所选非劣效界值的临床可接受性解读。
适用人群与场景
- 18岁及以上、前循环近端颅内闭塞、发病4.5小时内且适合静脉溶栓的急性缺血性卒中患者,纳入中国33家卒中中心。
诊断标准与关键阈值
- 90天功能独立定义为改良Rankin量表评分0-2分(范围0分无症状至6分死亡)。
- 非劣效界值为-10%。
处置流程与药物剂量
- 单纯血管内取栓组116例接受单纯血管内治疗。
- 联合治疗组118例接受静脉阿替普酶后血管内取栓(标准治疗)。
研究设计与关键结果
- 多中心随机非劣效试验,纳入234例(单纯取栓116例 vs 联合治疗118例),平均年龄68岁,女性102例(43.6%)。
- 90天功能独立:单纯取栓组63例(54.3%) vs 联合治疗组55例(46.6%),差异7.7%(单侧97.5%CI -5.1%至∞),非劣效P=0.003。
- 48小时内症状性颅内出血:单纯组6.1% vs 联合组6.8%,差异-0.8%(95%CI -7.1%至5.6%)。
- 90天死亡率:单纯组17.2% vs 联合组17.8%,差异-0.5%(95%CI -10.3%至9.2%)。
- 试验因疗效提前终止,实际随机234例(计划970例)。
证据类型、等级与局限
- 随机、多中心、非劣效性试验。
- 局限:试验因疗效提前终止,仅随机234例(计划970例);结论需结合所选非劣效界值的临床可接受性解读(原文结论指出)。
对床旁实践的改变
- 对前循环近端闭塞、发病4.5小时内且适合静脉溶栓的患者,单纯血管内取栓与静脉阿替普酶联合取栓相比,90天功能独立达到预设非劣效界值。
- 作者指出这些发现应结合所选非劣效界值的临床可接受性进行解读。
指南或共识出处
- DEVT随机临床试验,中国临床试验注册号ChiCTR-IOR-17013568。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: For patients with large vessel occlusion strokes, it is unknown whether endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment (standard treatment) can achieve similar functional outcomes.
OBJECTIVE: To investigate whether endovascular thrombectomy alone is noninferior to intravenous alteplase followed by endovascular thrombectomy for achieving functional independence at 90 days among patients with large vessel occlusion stroke.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, noninferiority trial conducted at 33 stroke centers in China. Patients (n = 234) were 18 years or older with proximal anterior circulation intracranial occlusion strokes within 4.5 hours from symptoms onset and eligible for intravenous thrombolysis. Enrollment took place from May 20, 2018, to May 2, 2020. Patients were enrolled and followed up for 90 days (final follow-up was July 22, 2020).
INTERVENTIONS: A total of 116 patients were randomized to the endovascular thrombectomy alone group and 118 patients to combined intravenous thrombolysis and endovascular thrombectomy group.
MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients achieving functional independence at 90 days (defined as score 0-2 on the modified Rankin Scale; range, 0 [no symptoms] to 6 [death]). The noninferiority margin was -10%. Safety outcomes included the incidence of symptomatic intracerebral hemorrhage within 48 hours and 90-day mortality.
RESULTS: The trial was stopped early because of efficacy when 234 of a planned 970 patients had undergone randomization. All 234 patients who were randomized (mean age, 68 years; 102 women [43.6%]) completed the trial. At the 90-day follow-up, 63 patients (54.3%) in the endovascular thrombectomy alone group vs 55 (46.6%) in the combined treatment group achieved functional independence at the 90-day follow-up (difference, 7.7%, 1-sided 97.5% CI, -5.1% to ∞)P for noninferiority = .003). No significant between-group differences were detected in symptomatic intracerebral hemorrhage (6.1% vs 6.8%; difference, -0.8%; 95% CI, -7.1% to 5.6%) and 90-day mortality (17.2% vs 17.8%; difference, -0.5%; 95% CI, -10.3% to 9.2%).
CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke due to proximal anterior circulation occlusion within 4.5 hours from onset, endovascular treatment alone, compared with intravenous alteplase plus endovascular treatment, met the prespecified statistical threshold for noninferiority for the outcome of 90-day functional independence. These findings should be interpreted in the context of the clinical acceptability of the selected noninferiority threshold.
TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR-IOR-17013568.
参考来源
- Zi W, Qiu Z, Li F, et al. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA. 2021. PMID: 33464335. doi:10.1001/jama.2020.23523
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。